Back to Search
Start Over
Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts
- Source :
- Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid, Consejería de Sanidad de la Comunidad de Madrid, CLINICAL CANCER RESEARCH, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, instname
- Publication Year :
- 2016
-
Abstract
- Purpose: Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin to anthracycline/taxane chemotherapy improves pathologic complete response (pCR) in triple-negative breast cancer (TNBC). Effectiveness of anthracycline-free platinum combinations in TNBC is not well known. Here, we report efficacy of NA carboplatin + docetaxel (CbD) in TNBC. Experimental Design: The study population includes 190 patients with stage I–III TNBC treated uniformly on two independent prospective cohorts. All patients were prescribed NA chemotherapy regimen of carboplatin (AUC 6) + docetaxel (75 mg/m2) given every 21 days × 6 cycles. pCR (no evidence of invasive tumor in the breast and axilla) and residual cancer burden (RCB) were evaluated. Results: Among 190 patients, median tumor size was 35 mm, 52% were lymph node positive, and 16% had germline BRCA1/2 mutation. The overall pCR and RCB 0 + 1 rates were 55% and 68%, respectively. pCRs in patients with BRCA-associated and wild-type TNBC were 59% and 56%, respectively (P = 0.83). On multivariable analysis, stage III disease was the only factor associated with a lower likelihood of achieving a pCR. Twenty-one percent and 7% of patients, respectively, experienced at least one grade 3 or 4 adverse event. Conclusions: The CbD regimen was well tolerated and yielded high pCR rates in both BRCA-associated and wild-type TNBC. These results are comparable with pCR achieved with the addition of carboplatin to anthracycline–taxane chemotherapy. Our study adds to the existing data on the efficacy of platinum agents in TNBC and supports further exploration of the CbD regimen in randomized studies. Clin Cancer Res; 23(3); 649–57. ©2016 AACR.
- Subjects :
- 0301 basic medicine
Oncology
Cancer Research
endocrine system diseases
medicine.medical_treatment
Genes, BRCA2
Genes, BRCA1
Triple Negative Breast Neoplasms
Docetaxel
urologic and male genital diseases
Carboplatin
Polyethylene Glycols
chemistry.chemical_compound
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
Multicenter Studies as Topic
Prospective Studies
Neoadjuvant therapy
Mastectomy
Aged, 80 and over
Kansas
Middle Aged
Chemotherapy regimen
Combined Modality Therapy
female genital diseases and pregnancy complications
Neoadjuvant Therapy
Observational Studies as Topic
Treatment Outcome
030220 oncology & carcinogenesis
Female
Taxoids
therapeutics
medicine.drug
Adult
medicine.medical_specialty
Filgrastim
Article
03 medical and health sciences
Breast cancer
Internal medicine
medicine
Humans
neoplasms
Aged
Gynecology
Chemotherapy
Taxane
business.industry
Carcinoma
medicine.disease
Regimen
030104 developmental biology
chemistry
Spain
Case-Control Studies
business
Subjects
Details
- ISSN :
- 15573265 and 10780432
- Volume :
- 23
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Clinical cancer research : an official journal of the American Association for Cancer Research
- Accession number :
- edsair.doi.dedup.....bd50e2c11440ff5ec0432f3033621cfe